Skip to main content

Table 3 Analysis of independent risk factors for tumor recurrence and overall survival

From: Antiviral therapy inhibited HBV-reactivation and improved long-term outcomes in patients who underwent radiofrequency ablation for HBV-related hepatocellular carcinoma

Variables

Tumor recurrence

Overall survival

Univariate

Multivariate

Univariate

Multivariate

HR

95% CI

P

HR

95% CI

P

HR

95% CI

P

HR

95% CI

P

Age, years

1.002

0.991–1.013

0.759

   

0.999

0.987–1.012

0.901

   

Sex, female: male

1.098

0.811–1.487

0.546

   

0.947

0.657–1.365

0.771

   

Diabetes mellitus, yes: no

1.171

0.862–1.590

0.313

   

1.064

0.745–1.520

0.732

   

AFP, μg/L ≥ 20, yes: no

1.148

0.925–1.425

0.212

   

1.174

0.919–1.501

0.200

   

Tumor number, single: multiple

1.556

1.220–1.986

 < 0.001

1.524

1.187–1.957

0.001

1.340

1.017–1.767

0.038

1.220

0.922–1.614

0.163

Liver cirrhosis, yes: no

1.821

1.436–2.308

 < 0.001

1.710

1.344–2.175

 < 0.001

1.887

1.450–2.456

 < 0.001

1.744

1.334–2.280

 < 0.001

Diameter, cm, ≤ 3: > 3

1.142

1.009–1.293

0.036

1.155

1. 013–1.316

0.031

1.076

0.939–1.234

0.290

   

BCLC staging 0: 1

1.079

0.842–1.382

0.547

   

0.977

0.740–1.289

0.867

   

ECOG, 0: 1: 2

1.042

0.856–1.269

0.682

   

0.997

0.798–1.245

0.978

   

Total bilirubin, μmol/L

1.011

0.998–1.025

0.100

   

1.015

1.001–1.030

0.040

1.002

0.985–1.020

0.794

Albumin, g/L

0.978

0.955–1.001

0.064

   

0.979

0.954–1.005

0.110

   

Platelets, 109/L

0.998

0.996–1.000

0.034

0.877

0.699–1.099

0.255

0.997

0.995–0.999

0.006

0.999

0.996–1.001

0.999

Prothrombin time, s

1.120

0.970–1.532

0.090

   

1.130

1.015–1.258

0.025

1.033

0.904–1.180

0.637

GGT, U/L

1.001

1.000–1.002

0.068

   

1.001

1.000–1.002

0.099

   

ALP, U/L

1.002

0.999–1.004

0.143

   

1.001

0.999–1.004

0.269

   

ALT, U/L

0.999

0.996–1.002

0.646

   

0.998

0.994–1.002

0.281

   

Creatinine, μmol/L

0.997

0.991–1.003

0.378

   

1.001

0.995–1.007

0.740

   

AFU, U/L

1.011

0.999–1.023

0.086

   

1.019

0.905–1.032

0.066

   

HBsAg, positive: negative

6.404

1.594–25.732

0.009

5.096

1.256–20.667

0.023

4.051

1.007–16.291

0.049

2.477

0.608–10.101

0.206

HBeAg, positive: negative

1.009

0.788–1.293

0.941

   

0.940

0.707–1.249

0.668

   

HBV-DNA, IU/mL, ≥ 2000: < 2000

1.528

1.229–1.901

 < 0.001

1.377

1.097–1.729

0.006

1.660

1.298–2.123

 < 0.001

1.566

1.208–2.029

0.001

AVT, yes: no

0.607

0.488–0.755

 < 0.001

0.578

0.463–0.722

 < 0.001

0.519

0.404–0.667

 < 0.001

0.509

0.395–0.657

 < 0.001

HBV reactivation, yes: no

1.475

1.062–2.049

0.020

1.427

1.014–2.009

0.041

1.477

1.041–2.094

0.029

1.377

0.954–1.987

0.088

  1. Abbreviations: HR Hazard ratio, CI Confidence interval, AFP Alpha-fetoprotein, BCLC Barcelona Clinic Liver Cancer, ECOG Eastern Cooperative Oncology Group score standard, GGT Gamma-glutamyl transferase, ALP Alkaline phosphatase, ALT Alanine aminotransferase, AFU α-L-fucosidase, HbsAg Hepatitis B surface antigen, HBeAg hepatitis B e antigen, AVT Antiviral therapy
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us